Climb Bio (CLYM) said Thursday it has signed an exclusive licensing deal with Beijing Mabworks Biotech to develop and commercialize anti-APRIL monoclonal antibody CLYM116 outside of Greater China to potentially treat patients with IgA nephropathy and other B-cell-mediated diseases.
Under the agreement, Climb Bio said it will pay $9 million upfront to Mabworks and make milestone payments as well as low- to mid-single-digit royalties on net sales outside of Greater China.
Climb Bio said it is conducting preclinical studies on CLYM116 and expects to share data later in 2025.
Additionally, the company said it had about $212.9 million in cash, cash equivalents and short-term marketable securities as of Dec. 31, which is expected to fund operations through 2027.
Price: 1.87, Change: -0.22, Percent Change: -10.53
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。